Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lorus Therapeutics LORFF LOR -- Ignore unavailable to you. Want to Upgrade?

To: mark calgary who wrote (40)	1/10/2000 8:04:00 AM
From: Gabe Heti	Read Replies (1) \| Respond to of 101

This was e-mailed to me by Stockwatch. Lorus Therapeutics fifth most active conference Lorus Therapeutics Inc LOR Shares issued 43,280,001 Jan 7 close $2.10 Mon 10 Jan 2000 Week ended Jan 7th by Stockwatch business reporter This is the first review of Lorus Therapeutics in Forum Watch, sliding into fifth position among Canada Stockwatch's most active conferences. Lorus is a pharmaceutical company engaged in the development of cancer therapies. In addition to trading on the Toronto and Montreal exchanges, Lorus trades on the Nasdaq OTC Bulletin Board under the symbol "LORFF". Lorus is currently developing a number of anticancer compounds called NuChem Analogues as well as a sterile liquid drug formulation for injection called Virulizin. At a special shareholders meeting on July 14, 1999, Lorus obtained shareholder approval for the acquisition of GeneSense Technologies, a private biopharmaceutical company. The acquisition of GeneSense and recent exercise of warrants has pushed the company's total shares outstanding to 140 million according to a Jan. 6 Globe and Mail report. On Dec. 7, Lorus announced that its application to begin trials of the anticancer drug, GTI 2040, had been approved by the U.S. Food and Drug Administration. The clinical trial will take place under the direction of Dr. Richard Schilsky of the Chicago Cancer Research Center. That announcement, coupled with renewed interest in the biotechnology sector, moved the stock price sharply higher. Lorus set a 52-week high of $3.10 on Jan 6. in brisk trading. The Lorus conference slipped into fifth position among the active conferences largely through default in a week of light posting. There was not any sustained or extensive discussion. Early in the week, 'Jag' offered some brief comments regarding recent news coverage, remarking that Lorus "is taking a leadership role in regards to the battle for control of cancer and from the activity on the market place the news was received very well!" On Jan. 3, 'Midas' joined in: "LOR seems to be in big demand trading as high as $1.08 today on the Nasdaq. That would be about $1.56 (Canadian)." 'Ziggy' offered some thoughts, remarking, "I read recently (National Post) that the company is spearheading a biotech consolidation in Canada, which may also be a part of their success in the markets." When Lorus closed at $1.31 (U.S.) on Monday, 'Midas' speculated on what the following day would bring, remarking, "We should have a strong opening and some frantic short covering to begin the day." 'Ziggy' agreed: "LOR should open above $2 tomorrow. Even at this price this may be a good play." As it turned out, Lorus did set a 52-week high on Thursday before closing out the week at $2.10. (c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com